A patient case demonstrating the efficacy of benralizumab in uncontrolled severe eosinophilic asthma refractory to omalizumab and mepolizumab treatment

A patient case demonstrating the efficacy of benralizumab in uncontrolled severe eosinophilic asthma refractory to omalizumab and mepolizumab treatment

Severe eosinophilic asthma is associated with a heavy burden and impact on daily living in patients experiencing uncontrolled symptoms, exacerbations, and treatment side effects. This case study reports a 49-year-old woman who presented to the severe asthma center with uncontrolled severe asthma des...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: John Davison, Simon Doe
Formato: article
Lenguaje:EN
Publicado: Elsevier 2021
Materias:
Benralizumab
Severe eosinophilic asthma
Biologics
Eosinophilia
Quality of life
Diseases of the respiratory system
RC705-779
Acceso en línea:https://doaj.org/article/80eca5f3ece644f09867e137f705a203
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:80eca5f3ece644f09867e137f705a203
record_format dspace
spelling oai:doaj.org-article:80eca5f3ece644f09867e137f705a2032021-11-26T04:28:41ZA patient case demonstrating the efficacy of benralizumab in uncontrolled severe eosinophilic asthma refractory to omalizumab and mepolizumab treatment2213-007110.1016/j.rmcr.2021.101557https://doaj.org/article/80eca5f3ece644f09867e137f705a2032021-01-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2213007121002197https://doaj.org/toc/2213-0071Severe eosinophilic asthma is associated with a heavy burden and impact on daily living in patients experiencing uncontrolled symptoms, exacerbations, and treatment side effects. This case study reports a 49-year-old woman who presented to the severe asthma center with uncontrolled severe asthma despite multiple maintenance medications and omalizumab treatment. On presentation, the patient had experienced two to three hospitalizations per year, frequent asthma exacerbations requiring courses of oral corticosteroids, and symptoms that impacted her quality of life. Omalizumab was previously discontinued, and bronchial thermoplasty was also unsuccessful. The patient stabilized on injectable steroids and commenced mepolizumab once available on prescription. Owing to continued exacerbations and an inability to reduce steroid treatment without exacerbating, mepolizumab was discontinued and the patient commenced benralizumab (30 mg subcutaneously every 4 weeks for the first three doses, every 8 weeks thereafter) under the sole care of the severe asthma center. Benralizumab treatment resulted in a reduction in steroid treatment, zero asthma exacerbations, improved asthma control and lung function, and a marked improvement in activity levels that allowed the patient to participate in a long-distance running event. Additionally, 7 months following the initiation of benralizumab treatment, her blood eosinophils were completely depleted. These findings support the use of benralizumab in patients with refractory uncontrolled severe eosinophilic asthma despite previous biologic treatment with omalizumab and mepolizumab, as improvements in clinical and patient outcomes, including quality of life, can be achieved in difficult-to-treat cases.John DavisonSimon DoeElsevierarticleBenralizumabSevere eosinophilic asthmaBiologicsEosinophiliaQuality of lifeDiseases of the respiratory systemRC705-779ENRespiratory Medicine Case Reports, Vol 34, Iss , Pp 101557- (2021)
institution DOAJ
collection DOAJ
language EN
topic Benralizumab
Severe eosinophilic asthma
Biologics
Eosinophilia
Quality of life
Diseases of the respiratory system
RC705-779
spellingShingle Benralizumab
Severe eosinophilic asthma
Biologics
Eosinophilia
Quality of life
Diseases of the respiratory system
RC705-779
John Davison
Simon Doe
A patient case demonstrating the efficacy of benralizumab in uncontrolled severe eosinophilic asthma refractory to omalizumab and mepolizumab treatment
description Severe eosinophilic asthma is associated with a heavy burden and impact on daily living in patients experiencing uncontrolled symptoms, exacerbations, and treatment side effects. This case study reports a 49-year-old woman who presented to the severe asthma center with uncontrolled severe asthma despite multiple maintenance medications and omalizumab treatment. On presentation, the patient had experienced two to three hospitalizations per year, frequent asthma exacerbations requiring courses of oral corticosteroids, and symptoms that impacted her quality of life. Omalizumab was previously discontinued, and bronchial thermoplasty was also unsuccessful. The patient stabilized on injectable steroids and commenced mepolizumab once available on prescription. Owing to continued exacerbations and an inability to reduce steroid treatment without exacerbating, mepolizumab was discontinued and the patient commenced benralizumab (30 mg subcutaneously every 4 weeks for the first three doses, every 8 weeks thereafter) under the sole care of the severe asthma center. Benralizumab treatment resulted in a reduction in steroid treatment, zero asthma exacerbations, improved asthma control and lung function, and a marked improvement in activity levels that allowed the patient to participate in a long-distance running event. Additionally, 7 months following the initiation of benralizumab treatment, her blood eosinophils were completely depleted. These findings support the use of benralizumab in patients with refractory uncontrolled severe eosinophilic asthma despite previous biologic treatment with omalizumab and mepolizumab, as improvements in clinical and patient outcomes, including quality of life, can be achieved in difficult-to-treat cases.
format article
author John Davison
Simon Doe
author_facet John Davison
Simon Doe
author_sort John Davison
title A patient case demonstrating the efficacy of benralizumab in uncontrolled severe eosinophilic asthma refractory to omalizumab and mepolizumab treatment
title_short A patient case demonstrating the efficacy of benralizumab in uncontrolled severe eosinophilic asthma refractory to omalizumab and mepolizumab treatment
title_full A patient case demonstrating the efficacy of benralizumab in uncontrolled severe eosinophilic asthma refractory to omalizumab and mepolizumab treatment
title_fullStr A patient case demonstrating the efficacy of benralizumab in uncontrolled severe eosinophilic asthma refractory to omalizumab and mepolizumab treatment
title_full_unstemmed A patient case demonstrating the efficacy of benralizumab in uncontrolled severe eosinophilic asthma refractory to omalizumab and mepolizumab treatment
title_sort patient case demonstrating the efficacy of benralizumab in uncontrolled severe eosinophilic asthma refractory to omalizumab and mepolizumab treatment
publisher Elsevier
publishDate 2021
url https://doaj.org/article/80eca5f3ece644f09867e137f705a203
work_keys_str_mv AT johndavison apatientcasedemonstratingtheefficacyofbenralizumabinuncontrolledsevereeosinophilicasthmarefractorytoomalizumabandmepolizumabtreatment
AT simondoe apatientcasedemonstratingtheefficacyofbenralizumabinuncontrolledsevereeosinophilicasthmarefractorytoomalizumabandmepolizumabtreatment
AT johndavison patientcasedemonstratingtheefficacyofbenralizumabinuncontrolledsevereeosinophilicasthmarefractorytoomalizumabandmepolizumabtreatment
AT simondoe patientcasedemonstratingtheefficacyofbenralizumabinuncontrolledsevereeosinophilicasthmarefractorytoomalizumabandmepolizumabtreatment
_version_ 1718409850401062912

Ejemplares similares